BTF3L4 is altered in 0.14% of all cancers with low-grade glioma, NOS, pancreatic adenocarcinoma, pilocytic astrocytoma, thyroid gland papillary carcinoma, and astrocytoma having the greatest prevalence of alterations .
The most common alteration in BTF3L4 is BTF3L4-BRAF Fusion (0.14%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.